As our model predicted, the trafficking distance from the tumor to the TDLNs can be associated with the fraction of antibody degradation in the lymphatic endothelial cells, even though FcRn can recycle a fraction of antibodies. The gene discussed is FCGRT; the disease is neoplasm.